News | June 03, 2022
Evonik to build new lipid production facility for mRNA-based therapies in U.S.
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
The production suspension impacts commercial and clinical trial supply
Company will expand the existing production site in Wuxi to significantly increase biopharma single-use assemblies and custom design capabilities
The plant is expected to start commercial operations from Q4FY24
All the capex is being met through internal accruals only
To meet the growing global demand for respiratory active pharmaceutical ingredients (APIs), Inke is to invest €9 million into its production plant to reinforce focus on inhalation micronised APIs
The new facility is scheduled to start operation in the first half of 2024
The investment will improve equipment efficiency and increase safety standards at its Lestrem site
The expansion reiterates BASF’s continued commitment to Asia Pacific and specifically to customers in the medical glove industry
Ritonavir oral tablet is a pharmacokinetic booster of multiple oral antiviral drugs targeting viral proteases and a component of the approved oral antiviral drug Paxlovid (Nirmatrelvir 300 mg tablet + ritonavir 100 mg tablet co-administration package)
Subscribe To Our Newsletter & Stay Updated
